December 2020 - Page 2 of 3 - PsychedelicNewsWire (PNW)

FridayDec 18, 2020 4:00 pm

How Retired Pro Athletes Use Psychedelics

Former UFC fighters Dean Lister and Ian McCall, former NHL player Daniel Carcillo and former NFL player Kerry Rhodes are a few well-known athletes who current using plant medicines such as psilocybin mushrooms and ayahuasca to help manage brain trauma symptoms and heal their PTSD. Carcillo suffered from mental and physical trauma following the effects of repeated concussions after retiring from the NHL. It wouldn’t have been easy to spot though, given that from the outside, he seemed to have it all — from a successful career to a comfortable home and a lovely family. CTE, or chronic traumatic encephalopathy,…

ThursdayDec 17, 2020 1:50 pm

Pure Extract Technologies (CSE: PULL) Provides Update on Expansion into Functional Mushrooms Sector

Pure Extracts Technologies recently provided update into its expansion into functional mushrooms sector Functional mushrooms have enjoyed surge in popularity as of late, are increasingly being used in wide variety of healthcare, pharmaceutical products Functional mushrooms sector is expected to grow to annual market value of $34.4 billion by 2024 Pure Extracts plans to develop high bio-available products derived from functional mushrooms through use of its proprietary extraction processes Company also set to launch its own branded functional mushrooms-based products under ‘Pure Mushrooms’ brand from Q1 2021 onwards and has signed a LOI with the PURICA(TM) brand of mushroom wellness…

ThursdayDec 17, 2020 1:30 pm

Functional vs. Psilocybin Mushrooms: A Guide to Investing

As psychedelics move into mainstream media, the attention on substances such as psilocybin and MDMA grows. Chances are good that you’ve heard of psilocybin mushrooms, but did you know that an entirely different category of mushrooms exists, nonpsychedelics that are called functional mushrooms. Examples of these mushrooms include reishi, chaga and lion’s mane. These two growing markets can both be considered as potential investment opportunities. Below, we look at their differences and examine the potential for growth and profit for investors. Wellness space or media spotlight: Which is better? Magic mushrooms are hallucinogenic mushrooms that have the psychoactive component psilocybin.…

WednesdayDec 16, 2020 3:00 pm

Canadian Government to Allow Therapists to Use Psilocybin Mushrooms

Canada’s Health Minister Patter Hajdu recently stated that the country would allow some health-care professionals to both consume and possess psilocybin mushrooms. The aim of this move is to provide a way that health-care professionals can better understand and recognize how to treat the increasing number of patients who have been allowed to use the psychedelic. This is the health ministry’s first public response to the psilocybin-use pending applications by therapists. Over the summer, the health ministry allowed a limited number of patients to use psilocybin mushrooms as part of their psychotherapy in their end-of-life care. However, ministry of health…

WednesdayDec 16, 2020 12:42 pm

Traditional Chinese Medicine Takes Root in Western Culture with Rritual Superfoods Product Line

Rritual Superfoods, Inc., is a budding new superfood developer aiming to improve people’s overall wellness with purposefully designed elixirs pairing acclaimed mushroom varieties with adaptogenic herbs The company was organized earlier this year and has launched three initial product varieties using the Chaga, Reishi and Lion’s Mane mushrooms in tandem with adaptogenic roots plus herbal spices and natural whole foods Rritual’s products are designed to help users combat stress, strengthen their immune systems and enhance their mental clarity The nascent functional mushroom market is expected to grow with a CAGR of 8.04 percent between 2019 and 2024, according to Mordor…

TuesdayDec 15, 2020 3:15 pm

Could Prejudices Be Holding Us Back from Accepting Psychedelics as Mental Health Treatment?

Current pharmaceutical drugs for depression seem to be causing more harm than good to their users, with some patients developing a resistance to treatments while others become dependent on the treatments. This may be a reason for the increase in interest in the use of psychedelic drugs as alternative and potentially safer treatments for depression and other mental health conditions. The first time psychedelics were studied as a potential mental-health treatment was several decades ago, when researchers studied the therapeutic potential of LSD. However, as decades passed and various national and international drug policies were implemented, further research exploring the…

TuesdayDec 15, 2020 1:41 pm

Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression

Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in depressive symptoms in adults with major depression, according to recent research conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry” (https://ibn.fm/AM1Ww). As a leading life sciences company focused on psychedelic drug development, Cybin…

MondayDec 14, 2020 12:00 pm

Tips to Becoming a Successful Psychedelic Retail Investor

The psychedelic medicine sector is booming and so is the interest in the market by investors. Pioneer clinical studies and research only help further this market along, bolstering its momentum. If you have an interest in investing in the market, here are a few things to take note of. Track projections and promises This may sound complicated, but it actually isn’t. Bonus: you don’t need training in finance to understand it. Tracking a firm’s profitability through its yearly projections is a simple way to find out whether a company’s results match its talk. Firms that fail to attain the targets…

FridayDec 11, 2020 3:00 pm

Psychedelics May Be the Next Big Investment Venture

The Controlled Substances Act was passed in the United States in the 1970s. The president at the time, Richard Nixon, approved the act as part of his war on drugs campaign. Under the act, cannabis was classified as a schedule 1 drug and was classified together with heroin and cocaine as extremely illegal and dangerous substances that were not allowed to be utilized in any medical applications. Currently, the legal cannabis market in the world is growing each year at an average of 40% and is valued at $17 billion. This is mainly attributed to the emerging research showing that…

ThursdayDec 10, 2020 1:45 pm

Billionaire Peter Thiel Invests in Psychedelic Drug Development

The mental health treatments being used around the world sometimes seem to be doing more harm than good to their consumers, with patients often becoming either addicted to their treatments or treatment resistant. Atai Life Sciences cofounder Florian Brand states that only 50% of individuals respond to selective serotonin reuptake inhibitors, which is the most common depression and anxiety treatment. In addition, this approach can take up to three months for an individual to notice any changes in their symptoms, and individuals have a 33% probability of their bodies resisting the treatment. Backed by its founders, Atai Life Sciences believes…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: December 2020